News Sentiment

PHAT sentiment intelligence

Phathom Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.61 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+12.6% over one week, +21.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 12.6% Price confirming higher
Trend fit Trend inactive 21.6% over four weeks
Fair value 18.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 39
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 6
GlobeNewswire 6
TradingKey 5
TradingView 5
simplywall.st 5
Investing.com 4
Stock Traders Daily 3

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 27
Analyst action 6
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 72
Stock Titan Direct company coverage

Phathom Pharmaceuticals (PHAT) officer surrenders 1,555 for tax withholding

Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., surrendered 1,555 shares of common stock at $11.035 per share on July 14, 2026, to satisfy tax withholding obligations related to restricted stock units. This F-code disposition means shares

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:41
Source
Stock Titan
TradingKey Direct company coverage

Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Phathom Pharmaceuticals Inc (PHAT), detailing its current price momentum score, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages, concluding wi

Tone
Negative 39/100
Event
Market update
Published
13 Jul 2026 21:11
Source
TradingKey
MarketBeat Direct company coverage

Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Jul 2026 $PHAT

As of June 30, 2026, Phathom Pharmaceuticals (PHAT) had 11.99 million shares sold short, marking a 7.44% increase from the prior report and representing 16.59% of the public float. The short interest ratio is 11.7 days to cover, indicating strong pessimism about the stock. The ar

Tone
Negative 38/100
Event
Market update
Published
10 Jul 2026 21:11
Source
MarketBeat
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (PHAT) Movement

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing strong near and mid-term sentiment, potentially extending to a long-term uptrend, although it is currently testing resistance. AI models suggest specific trading strategies, including a long position with a target of $12.31 a

Tone
Positive 68/100
Event
Analyst action
Published
09 Jul 2026 09:46
Source
Stock Traders Daily
TradingView Direct company coverage

Price to book forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT

This article displays the "Price to book forward" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) on the TradingView platform. It provides financial data and indicates that the market was closed at the time the information was presented. The content primarily lists naviga

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 09:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT

This article briefly mentions the "Price to sales forward" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). It appears to be a financial data point from TradingView, indicating a value change for the company. The rest of the content consists of navigation links and copyri

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 08:42
Source
TradingView
Finviz Direct company coverage

PHAT - Phathom Pharmaceuticals Inc Revenue Breakdown

This article provides a detailed financial breakdown for Phathom Pharmaceuticals Inc (PHAT), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, stock ownership details, and price performa

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 14:40
Source
Finviz
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in PHAT Response

This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), noting conflicting sentiment and a mid-channel oscillation pattern. It highlights an exceptional risk-reward setup targeting a 29.0% gain against a 0.3% risk, with specific entry, target, and stop-loss points for

Tone
Positive 66/100
Event
Analyst action
Published
28 Jun 2026 08:24
Source
Stock Traders Daily
TradingView Direct company coverage

Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT)

This article provides financial data and analyst estimates for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT). It covers details like current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. The content also addresses frequent

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

PHAT Forecast — Price Target — Prediction for 2027

This article provides a forecast for Phathom Pharmaceuticals, Inc. (PHAT) stock, including analyst price targets and future predictions for 2027. It details the company's recent stock performance, financial metrics like revenue and earnings, and upcoming events such as the next e

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 16:10
Source
TradingView
Moomoo Direct company coverage

Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating

Craig-Hallum has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Tone
Positive 76/100
Event
Analyst action
Published
25 Jun 2026 13:40
Source
Moomoo
Investing.com Direct company coverage

Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study

Phathom Pharmaceuticals has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The study enrolled 95 patients across 41 sites in th

Tone
Positive 66/100
Event
Market update
Published
23 Jun 2026 14:10
Source
Investing.com
Investing.com Canada Direct company coverage

Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com

Phathom Pharmaceuticals, Inc. has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The trial enrolled 95 patients and topline res

Tone
Positive 63/100
Event
Market update
Published
23 Jun 2026 12:20
Source
Investing.com Canada
Stock Titan Direct company coverage

Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026

Phathom Pharmaceuticals has completed enrollment for its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for adults with eosinophilic esophagitis (EoE), enrolling 95 patients across 41 U.S. sites. Topline results are anticipated in the fourth quarter of 2026. Positive outc

Tone
Positive 67/100
Event
Earnings
Published
23 Jun 2026 11:59
Source
Stock Titan
Stock Titan Direct company coverage

Phathom enrolls 95 adults in VOQUEZNA EoE trial; results due in Q4

Phathom Pharmaceuticals has completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study for VOQUEZNA as a treatment for eosinophilic esophagitis (EoE), enrolling 95 adult patients across 41 U.S. sites. Topline results for the 12-week double-blind portion o

Tone
Positive 71/100
Event
Earnings
Published
23 Jun 2026 11:58
Source
Stock Titan
GlobeNewswire Direct company coverage

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals has completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA® (vonoprazan) as a treatment for eosinophilic esophagitis (EoE) in adults. The study, which enrolled 95 patients, is the first large, pla

Tone
Positive 69/100
Event
Market update
Published
23 Jun 2026 11:58
Source
GlobeNewswire
Investing.com Direct company coverage

Phathom completes enrollment in vonoprazan trial for EoE

Phathom Pharmaceuticals Inc. announced the completion of enrollment for its Phase 2 clinical trial evaluating vonoprazan tablets for eosinophilic esophagitis (EoE), involving 95 adult patients across 41 U.S. sites. Topline results are expected in Q4 2026. The company, which has s

Tone
Positive 64/100
Event
Earnings
Published
23 Jun 2026 08:10
Source
Investing.com
富途牛牛 Direct company coverage

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven?

This article analyzes Phathom Pharmaceuticals, Inc.'s path to profitability, focusing on analyst expectations for when the company will reach breakeven. It reviews the pharmaceutical company's financial performance, including its cash burn rates and anticipated revenue growth, to

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jun 2026 16:40
Source
富途牛牛
TradingKey Direct company coverage

Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis

Phathom Pharmaceuticals Inc (PHAT) currently has a valuation score of 8.43, placing it 94th out of 157 in the Pharmaceuticals industry. The article notes that relevant data for P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet, suggesting a lack of compreh

Tone
Negative 41/100
Event
Market update
Published
18 Jun 2026 09:09
Source
TradingKey
TradingKey Direct company coverage

Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis

Phathom Pharmaceuticals Inc (PHAT) has a stable financial score of 8.16, ranking 74th in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a significant year-over-year revenue increase of 104.43% to $58.30 million and a net profit increase o

Tone
Positive 75/100
Event
Earnings
Published
18 Jun 2026 02:09
Source
TradingKey
Investing.com Direct company coverage

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright has reiterated a Buy rating for Phathom Pharmaceuticals (NASDAQ:PHAT) with a $26 price target, citing substantial upside from its current $10.43 stock price. The firm's positive outlook follows a webinar highlighting clinical enthusiasm for Phathom's drug VOQUEZNA

Tone
Positive 71/100
Event
Analyst action
Published
17 Jun 2026 23:10
Source
Investing.com
TradingKey Direct company coverage

Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Phathom Pharmaceuticals Inc (PHAT). It notes that PHAT has not distributed any dividends over the past five years and shows no record of stock splits. The company's current stock performance and market capita

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:39
Source
TradingKey
TradingKey Direct company coverage

Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Phathom Pharmaceuticals Inc (PHAT), outlining major shareholders, institutional holdings, and related ETF investments. Key shareholders include Frazier Life Sciences Management, L.P. and Medicxi Ventures (UK) LLP, with significant

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 19:39
Source
TradingKey
GuruFocus Direct company coverage

PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26

HC Wainwright & Co. has reiterated a "Buy" rating for Phathom Pharmaceuticals (PHAT), maintaining its price target at $26. Despite this positive analyst sentiment, the company's GF Score™ is 27/100, reflecting low financial strength and profitability, though it shows positive mom

Tone
Positive 65/100
Event
Analyst action
Published
17 Jun 2026 11:39
Source
GuruFocus